TLP
AMLX icon

Tri Locum Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tri Locum Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-282,862
Closed -$5.18M – 27
2023
Q3 		$5.18M Buy
+282,862
New +$5.98M 1.66% 22
2022
Q3 		– Sell
-80,459
Closed -$1.55M – 46
2022
Q2 		$1.55M Buy
+80,459
New +$955K 0.63% 30

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's AMLX Position: Q4 2023 in Review

Tri Locum Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 282,862 shares — an estimated $5.18M sold.

Tri Locum Partners first reported a position in AMLX in Q2 2022 and held it in 2 quarters. The position peaked at $5.18M in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Tri Locum Partners reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 282,862 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $5.18M.
  • Tri Locum Partners first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Tri Locum Partners's Amylyx Pharmaceuticals position peaked at $5.18M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.